Autor: |
Dendreon Pharmaceuticals |
Zdroj: |
Business Wire (English). 03/12/2020. |
Abstrakt: |
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced findings from a sub-analysis of data from its PROCEED registry comparing overall survival (OS) in African American (AA) and Caucasian (CAU) men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with PROVENGE® (sipuleucel-T) in a real-world treatment setting. [ABSTRACT FROM PUBLISHER] |
Databáze: |
Regional Business News |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|